Synthesis and antitumor activity of 1,5,6-substituted E-3-(2-chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones

被引:32
作者
Andreani, A
Granaiola, M
Leoni, A
Locatelli, A
Morigi, R
Rambaldi, M
Garaliene, V
机构
[1] Univ Bologna, Dipartimento Sci Farmaceut, I-40126 Bologna, Italy
[2] Lithuanian Inst Cardiol, LT-3007 Kaunas, Lithuania
关键词
D O I
10.1021/jm011123c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Synthesis and antitumor activity of new E-3-(2-chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones are described. All compounds prepared were active in the primary test (three human cell lines) and entered the second level (60 human cell lines). The most active antitumor derivatives bear the same substituents in the chloroindole ring and are not CDK1 inhibitors. A COMPARE analysis showed that they could act as tubulin binders. In most cell lines, E-3-(2-chloro-5-methoxy-6-methyl-3-indolylmethylene)-1,3-dihydroindol-2-one was a growth inhibitor more potent than vincristine.
引用
收藏
页码:2666 / 2669
页数:4
相关论文
共 10 条
  • [1] Synthesis and potential coanthracyclinic activity of pyridylmethylene and indolylmethylene lactams
    Andreani, A
    Locatelli, A
    Leoni, A
    Morigi, R
    Chiericozzi, M
    Fraccari, A
    Galatulas, I
    Salvatore, G
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1998, 33 (11) : 905 - 909
  • [2] Potential antitumor agents. Part 29: Synthesis and potential coanthracyclinic activity of imidazo[2,1-b]thiazole guanylhydrazones
    Andreani, A
    Leoni, A
    Locatelli, A
    Morigi, R
    Rambaldi, M
    Recanatini, M
    Garaliene, V
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (09) : 2359 - 2366
  • [3] Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones
    Andreani, A
    Locatelli, A
    Leoni, A
    Rambaldi, M
    Morigi, R
    Bossa, R
    Chiericozzi, M
    Fraccari, A
    Galatulas, I
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1997, 32 (11) : 919 - 924
  • [4] Andreani A, 1996, ANTICANCER RES, V16, P3585
  • [5] Andreani A, 2001, ANTI-CANCER DRUG DES, V16, P167
  • [6] ANDREANI A, 1979, FARMACO-ED SCI, V34, P132
  • [7] Andreani A, 2000, ANTI-CANCER DRUG DES, V15, P447
  • [8] Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
    Meijer, L
    Borgne, A
    Mulner, O
    Chong, JPJ
    Blow, JJ
    Inagaki, N
    Inagaki, M
    Delcros, JG
    Moulinoux, JP
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 527 - 536
  • [9] FEASIBILITY OF A HIGH-FLUX ANTICANCER DRUG SCREEN USING A DIVERSE PANEL OF CULTURED HUMAN TUMOR-CELL LINES
    MONKS, A
    SCUDIERO, D
    SKEHAN, P
    SHOEMAKER, R
    PAULL, K
    VISTICA, D
    HOSE, C
    LANGLEY, J
    CRONISE, P
    VAIGROWOLFF, A
    GRAYGOODRICH, M
    CAMPBELL, H
    MAYO, J
    BOYD, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) : 757 - 766
  • [10] Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation
    Sielecki, TM
    Boylan, JF
    Benfield, PA
    Trainor, GL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (01) : 1 - 18